Guillermo A.
Guillermo A. Ameer, Chicago, IL US
Patent application number | Description | Published |
---|---|---|
20100034897 | Method for Removal or Inactivation of Heparin - The present invention relates to the use of immobilized RAGE or portions thereof for removal of heparin and low molecular weight heparin from a fluid sample or from a patient in need of neutralization of anticoagulant activity. The invention provides a method for removal or inactivation of heparin and low molecular weight heparin, as well as a device which utilizes this method. | 02-11-2010 |
20100036476 | Controlled and Localized Release of Retinoids to Improve Neointimal Hyperplasia - Controlled release vascular implants, such as vascular grafts, stents, wraps, and gels comprising a biocompatible polymer and all trans retinoic acid (ATRA), or its derivatives, can be used to treat, prevent, or inhibit thrombosis and/or neointimal hyperplasia which may otherwise be induced by prosthetic implantation. In particular, the implants herein can inhibit smooth muscle cell proliferation, neointimal hyperplasia, and upregulate antithrombotic genes and nitric oxide production in the vasculature. Further, the implants are capable of delivering controlled and predictable localized concentrations of ATRA. | 02-11-2010 |
20110082421 | Receptor-Based Blood Detoxification System - The invention discloses compositions of matter and methods of using such compositions to detoxify blood and blood products. The invention as particular use in the treatment of diabetes, Alzheimer's disease, hemodialysis associated amyloidosis, and cardiovascular complications. | 04-07-2011 |
20130195828 | Pharmaceutical Compositions and Methods for Digesting Atherosclerotic Plaques - Disclosed are pharmaceutical compositions and methods for digesting atherosclerotic plaques in a patient in need thereof. The compositions include and the methods utilize a mixture of collagenases for digesting plaques and optionally may include or utilize additional agents such as cyclodextrins, chelating agents, and tissue plasminogen activator. | 08-01-2013 |
20130211500 | Liquid Cast Biodegradable Arterial Stent - Disclosed are liquid cast biodegradable arterial stents and methods for preparing liquid cast biodegradable arterial stents. The typically includes a biodegradable polymer and may include an agent for treating neointimal hyperplasia. | 08-15-2013 |
20140322190 | Pharmaceutical Compositions and Methods for Digesting Atherosclerotic Plaques - Disclosed are pharmaceutical compositions and methods for digesting atherosclerotic plaques in a patient in need thereof. The compositions include and the methods utilize a mixture of collagenases for digesting plaques and optionally may include or utilize additional agents such as cyclodextrins, chelating agents, and tissue plasminogen activator. | 10-30-2014 |
20150071984 | Controlled and Localized Release of Retinoids to Improve Neointimal Hyperplasia - Controlled release vascular implants, such as vascular grafts, stents, wraps, and gels comprising a biocompatible polymer and all trans retinoic acid (ATRA), or its derivatives, can be used to treat, prevent, or inhibit thrombosis and/or neointimal hyperplasia which may otherwise be induced by prosthetic implantation. In particular, the implants herein can inhibit smooth muscle cell proliferation, neointimal hyperplasia, and upregulate antithrombotic genes and nitric oxide production in the vasculature. Further, the implants are capable of delivering controlled and predictable localized concentrations of ATRA. | 03-12-2015 |
Guillermo A. Arispe, Plano, TX US
Patent application number | Description | Published |
---|---|---|
20110134795 | UNIFIED NETWORK PLANNING AND PROVISIONING - An exemplary system includes a network systems database storing order information and diversity information and a link utilization database storing link utilization information. A data manager is configured to validate diversity and link utilization of the order information using the link utilization information and the diversity information. An exemplary method includes storing order information and diversity information in the network systems database, and storing link utilization information in the link utilization database. The method further includes accessing the order information, the diversity information, and the link utilization information with the data manager, and validating diversity and link utilization of the order information with the data manager using the link utilization information and the diversity information. | 06-09-2011 |
Guillermo A. Calero, Pittsburgh, PA US
Patent application number | Description | Published |
---|---|---|
20090204374 | Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents - Systems and methods for modeling the interactions of the several genes, proteins and other components of a cell, employing mathematical techniques to represent the interrelationships between the cell components and the manipulation of the dynamics of the cell to determine which components of a cell may be targets for interaction with therapeutic agents. A first such method is based on a cell simulation approach in which a cellular biochemical network intrinsic to a phenotype of the cell is simulated by specifying its components and their interrelationships. The various interrelationships are represented with one or more mathematical equations which are solved to simulate a first state of the cell. The simulated network is then perturbed by deleting one or more components, changing the concentration of one or more components, or modifying one or more mathematical equations representing the interrelationships between one or more of the components. The equations representing the perturbed network are solved to simulate a second state of the cell which is compared to the first state to identify the effect of the perturbation on the state of the network, thereby identifying one or more components as targets. A second method for identifying components of a cell as targets for interaction with therapeutic agents is based upon an analytical approach, in which a stable phenotype of a cell is specified and correlated to the state of the cell and the role of that cellular state to its operation. A cellular biochemical network believed to be intrinsic to that phenotype is then specified by identifying its components and their interrelationships and representing those interrelationships in one or more mathematical equations. The network is then perturbed and the equations representing the perturbed network are solved to determine whether the perturbation is likely to cause the transition of the cell from one phenotype to another, thereby identifying one or more components as targets. | 08-13-2009 |
Guillermo A. Vedani, Easley, SC US
Patent application number | Description | Published |
---|---|---|
20130146695 | JOURNAL BRUSH SEAL ASSEMBLIES - A brush seal assembly for sealing a journal assembly includes a base flange configured and adapted to be mounted to a journal head, e.g., in a vertical pulverizer. A cylindrical skirt is mounted to the base flange and extends in an axial direction from the base flange. A seal mounting ring is mounted to the skirt opposite the base flange, and an annular brush seal is mounted to the seal mounting ring. The brush seal is configured and adapted to seal between the skirt and a journal housing. | 06-13-2013 |